Category

Best Startup

Product/Solution Name

RESOLVIX

Date of Approval

N/A

Indications

inflammatory and degenerative conditions

Therapeutic Categories

resolutive pharmacology

Attached Files:
- RESOLVIXx.jpg

Background information and need for solution/product

Today, chronic inflammation is considered as the main leading cause of life-threating diseases such as cardiovascular diseases, cancer, diabetes, degenerative diseases... More than 400 millions people suffer from chronic inflammatory diseases such as rheumatoid arthritis, Crohn disease.... with no cure available. Most of the systemic drug approaches using small molecules and biologics developed in recent years have failed to durably control or reverse chronic inflammation and present deleterious side effects.
A new type pharmacology, named resolution pharmacology, was proposed a couple of decades ago that, in stark contrast to the classic anti-inflammatory pharmacology, does not inhibit or destruct the immune system function (as has been highlighted for the care of covid patients for instance) but exploit the biological processes of the resolution phase of inflammation to restore the natural control of inflammation and tissue healing.
Cure are needed and in particular 100% human-origin biological drugs.

Attached Files:
- SYNTHESISv4s.jpg

History of the development of the solution/product

Chronic inflammatory diseases have in common a dysregulation of the termination process of inflammation, which persists and settles down permanently, destructing tissues.

Because inflammation is a natural biological and protective process of the body, at MIP we looked for and identified the molecules terminating inflammation in normal conditions. Then we conditioned human cells by reproducing inflammation resolution, and simply collected and transformed such molecules into a therapeutic cell-free serum.

Attached Files:

- Tech.jpg

Why this solution/product is innovative, the broad implications for future research, and/or how it will improve the human condition

At MIP we develop resolution pharmacology drug candidates based on our proprietary breakthrough technology. That technology allows the production of 100% human and biological drug candidate, manufactured by human cells and composed of a perfect set of molecules dedicated to the long term treatment of chronic and degenerative diseases.

Our lead candidate RESOLVIX, in clinical stage, should be test for innocuity and preliminary efficacy in 2023 in the treatment of a rare and orphan disease, systemic sclerosis. RESOLVIX will restore dysregulated resolution of inflammation and provide the molecules necessary to efficiently activate and terminate natural resolution of inflammation. Its main target among stem cell attraction to renew tissues are inflammatory macrophages which are deeply reprogram at the epigenetic level to resolutive macrophages.

Interestingly, such an approach is compatible where resolution is dysregulated, thus in inflammatory conditions, degenerative diseases, cancer... With future positive data of our lead candidate RESOLVIX, we will be able to quickly develop cell-free resolutive serums in such indications and strongly improve the human condition.

Attached Files:

- resolvix.jpg

Please provide appropriate references (ie Pubmed links)

Resolution therapy: Harnessing efferocytic macrophages to trigger the resolution of inflammation.
Saas P, Vetter M, Maraux M, Bonnefoy F, Perruche S.Front Immunol. 2022 Oct 28;13:1021413. doi: 10.3389/fimmu.2022.1021413. eCollection 2022.PMID: 36389733 Free PMC article. Review.

Editorial: Molecular and Cellular Effectors in the Resolution of Inflammation.
Ariel A, Perruche S, You S, Filep JG.Front Immunol. 2022 May 26;13:938819. doi: 10.3389/fimmu.2022.938819. eCollection 2022.PMID: 35693777 Free PMC article. No abstract available.

Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells.
Wetzel A, Bonnefoy F, Chagué C, Vetter M, Couturier M, Baffert B, Adotévi O, Saas P, Perruche S.Front Immunol. 2022 Jan 18;12:812171. doi: 10.3389/fimmu.2021.812171. eCollection 2021.PMID: 35116038 Free PMC article.

Pro-Resolving Factors Released by Macrophages After Efferocytosis Promote Mucosal Wound Healing in Inflammatory Bowel Disease.
Martin-Rodriguez O, Gauthier T, Bonnefoy F, Couturier M, Daoui A, Chagué C, Valmary-Degano S, Gay C, Saas P, Perruche S.Front Immunol. 2021 Dec 22;12:754475. doi: 10.3389/fimmu.2021.754475.

eCollection 2021.PMID: 35003066 Free PMC article.

Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.
Perez-Hernandez J, Chiurchiù V, Perruche S, You S.Front Immunol. 2021 Nov 16;12:768133. doi: 10.3389/fimmu.2021.768133. eCollection 2021.PMID: 34868025 Free PMC article. Review.

Factors Produced by Macrophages Eliminating Apoptotic Cells Demonstrate Pro-Resolutive Properties and Terminate Ongoing Inflammation.
Bonnefoy F, Gauthier T, Vallion R, Martin-Rodriguez O, Missey A, Daoui A, Valmary-Degano S, Saas P, Couturier M, Perruche S.Front Immunol. 2018 Nov 13;9:2586. doi: 10.3389/fimmu.2018.02586. eCollection 2018.PMID: 30542342 Free PMC article.